Myelodysplastic Syndrome Drugs Market Size, Share & Trends Analysis By Therapeutic Class (Hypomethylating Agents, Immunomodulatory Drugs, Anti-anemics), And Segment Forecasts, 2016 - 2022

Table of Contents

Chapter 1 Research Methodology
                  1.1 Information Procurement
                  1.2 Information or Data Analysis
                      1.2.1 Market formulation & validation
Chapter 2 Executive Summary
Chapter 3 Disease Primer and Epidemiology
                  3.1 Disease Primer
                      3.1.1 Types
                      3.1.2 Epidemiology
                      3.1.3 Current prevalence and incidence for seven major markets (U.S., Japan, EU5)
Chapter 4 Global Market Overview
                  4.1 Market by Treatment
                      4.1.1 Supportive Therapy
                          4.1.1.1 Blood transfusions
                          4.1.1.2 Iron chelation therapy
                          4.1.1.3 Growth factors
                      4.1.2 Chemotherapy
                      4.1.3 Stem cell transplantation
                  4.2 Market by Therapeutic Class
                      4.2.1 Hypomethylating agents
                      4.2.2 Immunomodulatory drugs
                      4.2.3 Anti-anemics
                  4.3 Market Size & Forecast
                  4.4 Sales Performance
                      4.4.1 Sales performance, by drug class (2016 - 2022)
                      4.4.2 Sales performance, by countries (2016 - 2022)
                      4.4.3 Sales performance, by company (2016 - 2022)
                  4.5 Market Share Distribution
                  4.6 Market Dynamics and Brand Strategies
                  4.7 Patent Expiry Schedule
                  4.8 Drivers and Challenges
                  4.9 M&A, Deal Landscape (2013-2017 YTD)
                  4.10 Pricing and Reimbursement
                  4.11 SWOT
Chapter 5 Pipeline Intelligence
                  5.1 Pipeline Landscape
                      5.1.1 Leading drugs in development
                      5.1.2 Key R&D trends
                  5.2 Promising Drug Candidates in Pipeline
                      5.2.1 Late stage pipeline analysis
                      5.2.2 Profile of disruptive drugs
                          5.2.2.1 Luspatercept (ACE-536)
                          5.2.2.2 Aranesp (Darbepoetin alfa)
                  5.3 Global Pipeline Forecast
Chapter 6 Competitive Landscape
                  6.1 Celgene
                      6.1.1 Company overview
                      6.1.2 Current product portfolio-Major products
                      6.1.3 Product forecast sales up to 2022
                      6.1.4 Strategic initiatives (Celgene)
                          6.1.4.1 Key company news flow
                      6.1.5 Pipeline overview
                      6.1.6 SWOT
                  6.2 Amgen
                      6.2.1 Company overview
                      6.2.2 Current product portfolio-Major products
                      6.2.3 Product forecast sales up to 2022
                      6.2.4 Strategic initiatives (Amgen)
                          6.2.4.1 Key company news flow
                      6.2.5 Pipeline analysis & overview
                      6.2.6 SWOT
                  6.3 Otsuka
                      6.3.1 Company overview
                      6.3.2 Current product portfolio-Major products
                      6.3.3 Product forecast sales up to 2022
                      6.3.4 Strategic initiatives (Otsuka)
                          6.3.4.1 Key company news flow
                      6.3.5 Pipeline analysis & overview
                      6.3.6 SWOT
                  6.4 Takeda
                      6.4.1 Company overview
                      6.4.2 Current product portfolio-Major products
                      6.4.3 Product forecast sales up to 2022
                      6.4.4 Strategic initiatives (Takeda)
                          6.4.4.1 Key company news flow
                      6.4.5 Pipeline analysis & overview
                      6.4.6 SWOT
Chapter 7 Market Outlook
                  7.1 What the future holds
                  7.2 Winners and losers
                  7.3 Emerging companies
                  7.4 The road ahead

List of Tables

TABLE 1 Sales Performance, by Drug Class (in $ million)
TABLE 2 Sales Performance, by Countries (in $ million)
TABLE 3 Sales Performance, by Company (in $ million)
TABLE 4 Patent Expiry Schedule
TABLE 5 R&D Pipeline Overview
TABLE 6 Late Stage Pipeline
TABLE 7 Product Profile: Luspatercept (ACE-536)
TABLE 8 Product Profile: Aranesp (Darbepoetin alfa)
TABLE 9 Global Pipeline Forecast
TABLE 10 Product Portfolio: Vidaza
TABLE 11 Product Portfolio: Revlimid
TABLE 12 Product Portfolio: Luspatercept
TABLE 13 Vidaza Sales Forecast, 2016 - 2022 (in $ million)
TABLE 14 Revlimid Sales Forecast, 2016 - 2022 (in $ million)
TABLE 15 Luspatercept Sales Forecast, 2016 - 2022 (in $ million)
TABLE 16 Pipeline (Celgene)
TABLE 17 Product Portfolio: Aranesp
TABLE 18 Aranesp Sales Forecast, 2016 - 2022 (in $ million)
TABLE 19 Pipeline (Amgen)
TABLE 20 Product Portfolio: Dacogen
TABLE 21 Product Portfolio: Guadecitabine
TABLE 22 Guadecitabine Sales Forecast, 2016 - 2022 (in $ million)
TABLE 23 Pipeline (Otsuka)
TABLE 24 Product Portfolio: Pevonedistat
TABLE 25 Pevonedistat Sales Forecast, 2016 - 2022 (in $ million)
TABLE 26 Pipeline (Takeda)

List of Figures

FIG. 1 Market research process
FIG. 2 Information Procurement
FIG. 3 Primary research pattern
FIG. 4 Market research approaches
FIG. 5 Value chain based sizing & forecasting
FIG. 6 QFD modelling for market share assessment
FIG. 7 MDS Age-Adjusted Incidence Rates, per 100,000 Population, by Race - 2014
FIG. 8 MDS Age-Adjusted Incidence Rates, per 100,000 Population, by Age - 2014
FIG. 9 Myelodysplastic Syndrome Drugs Market by Therapeutic Class (2016 & 2022)
FIG. 10 Myelodysplastic Syndrome Drugs Market, $ million (2016 & 2022)
FIG. 11 Market Share Distribution (2016 & 2022)
FIG. 12 Regional Share Distribution (2016 & 2022)
FIG. 13 Myelodysplastic Syndrome Drugs Market SWOT
FIG. 14 SWOT Analysis (Celgene)
FIG. 15 SWOT Analysis (Amgen)
FIG. 16 SWOT Analysis (Otsuka)
FIG. 17 SWOT Analysis (Takeda)